Isamu Sugimoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Isamu Sugimoto has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
Hisao Nakai
10 shared publicationsMasaaki Toda
Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan
9 shared publicationsAkira Matsuda
Graduate School of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan
8 shared publicationsSatoshi Shuto
Graduate School of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan
7 shared publicationsAtsushi Kinoshita
Medicinal Chemistry Research Laboratories, Department of Biology & Pharmacology, and Discovery Research Alliance, Ono Pharmaceutical Co., Ltd. , 3-1-1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan
5 shared publicationsShuichi Ohuchida
Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan
5 shared publications
Latest Publications
- Open Access
Development of a novel high-throughput screen for the identification of new inhibitors of protein S-acylation
Protein S-acylation is a reversible post-translational modification that modulates the localisation and function of many cellular proteins. S-acylation is mediated by a family of zinc finger DHHC domain-containing proteins encoded by 23 distinct ZDHHC genes in the human genome. These enzymes catalyse S-acylation in a two-step process involving “auto-acylation” of the cysteine residue in the catalytic DHHC motif followed by transfer of the acyl chain to a substrate cysteine. S-acylation is essential for many fundamental physiological processes, and there is growing interest in zDHHC enzymes as novel drug targets for a range of disorders. However, there is currently a lack of chemical modulators of S-acylation either for use as tool compounds or for potential development for therapeutic purposes. In this study, we developed and implemented a novel FRET-based high throughput assay for the discovery of compounds that interfere with auto-acylation of zDHHC2, an enzyme that is implicated in neuronal S-acylation pathways. A screen of >350,000 compounds identified two related tetrazole containing compounds (TTZ-1 and -2) that inhibited both zDHHC2 auto-acylation and substrate S-acylation in cell-free systems. Furthermore, these compounds were also active in HEK293T cells, where they inhibited substrate S-acylation mediated by different zDHHC enzymes, with some apparent isoform selectivity. Resynthesis of the hit compounds confirmed their activity, providing sufficient quantities of material for further investigations. The assays developed herein provide novel strategies to screen for zDHHC inhibitors, and the identified compounds add to the chemical toolbox for interrogating the cellular activities of S-acylation and zDHHC enzymes.
Open AccessDevelopment of a novel high-throughput screen for the identification of new inhibitors of protein S-acylation
Protein S-acylation is a reversible post-translational modification that modulates the localisation and function of many cellular proteins. S-acylation is mediated by a family of zinc finger DHHC domain-containing proteins encoded by 23 distinct ZDHHC genes in the human genome. These enzymes catalyse S-acylation in a two-step process involving “auto-acylation” of the cysteine residue in the catalytic DHHC motif followed by transfer of the acyl chain to a substrate cysteine. S-acylation is essential for many fundamental physiological processes, and there is growing interest in zDHHC enzymes as novel drug targets for a range of disorders. However, there is currently a lack of chemical modulators of S-acylation either for use as tool compounds or for potential development for therapeutic purposes. In this study, we developed and implemented a novel FRET-based high throughput assay for the discovery of compounds that interfere with auto-acylation of zDHHC2, an enzyme that is implicated in neuronal S-acylation pathways. A screen of >350,000 compounds identified two related tetrazole containing compounds (TTZ-1 and -2) that inhibited both zDHHC2 auto-acylation and substrate S-acylation in cell-free systems. Furthermore, these compounds were also active in HEK293T cells, where they inhibited substrate S-acylation mediated by different zDHHC enzymes, with some apparent isoform selectivity. Resynthesis of the hit compounds confirmed their activity, providing sufficient quantities of material for further investigations. The assays developed herein provide novel strategies to screen for zDHHC inhibitors, and the identified compounds add to the chemical toolbox for interrogating the cellular activities of S-acylation and zDHHC enzymes.
- 16 December 2016
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 8 (1) , 107-112
Discovery of Novel Seven-Membered Prostacyclin Analogues as Potent and Selective Prostaglandin FP and EP3 Dual Agonists
A novel series of prostaglandin analogues with a seven-membered ring scaffold was designed, synthesized, and evaluated for the functional activation of prostaglandin receptors to identify potent and subtype-selective FP and EP3 dual agonists. Starting from the prostacyclin derivative 5b, a nonselective agonist for prostaglandin receptors, replacement of the core structure with an octahydro-2H-cyclopenta[b]oxepine scaffold led to the discovery of the potent and selective FP and EP3 dual agonist 11b as a lead compound for the development of an antiglaucoma agent.
- 16 December 2016
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 8 (1) , 107-112
Discovery of Novel Seven-Membered Prostacyclin Analogues as Potent and Selective Prostaglandin FP and EP3 Dual Agonists
A novel series of prostaglandin analogues with a seven-membered ring scaffold was designed, synthesized, and evaluated for the functional activation of prostaglandin receptors to identify potent and subtype-selective FP and EP3 dual agonists. Starting from the prostacyclin derivative 5b, a nonselective agonist for prostaglandin receptors, replacement of the core structure with an octahydro-2H-cyclopenta[b]oxepine scaffold led to the discovery of the potent and selective FP and EP3 dual agonist 11b as a lead compound for the development of an antiglaucoma agent.
- 5 January 2016
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 7 (3) , 306-311
Discovery of G Protein-Biased EP2 Receptor Agonists
- 5 January 2016
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 7 (3) , 306-311
Discovery of G Protein-Biased EP2 Receptor Agonists
- 1 January 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 20 (2) , 1122-1138
Pyrrolo[1,2-b]pyridazines, pyrrolo[2,1-f]triazin-4(3H)-ones, and related compounds as novel corticotropin-releasing factor 1 (CRF1) receptor antagonists
- 1 January 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 20 (2) , 1122-1138
Pyrrolo[1,2-b]pyridazines, pyrrolo[2,1-f]triazin-4(3H)-ones, and related compounds as novel corticotropin-releasing factor 1 (CRF1) receptor antagonists
- 1 April 2010
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (8) , 2639-2643
Discovery of novel N-acylsulfonamide analogs as potent and selective EP3 receptor antagonists
- 1 April 2010
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (8) , 2639-2643
Discovery of novel N-acylsulfonamide analogs as potent and selective EP3 receptor antagonists
- 1 September 2009
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 17 (18) , 6567-6582
Discovery of a series of acrylic acids and their derivatives as chemical leads for selective EP3 receptor antagonists
- 1 September 2009
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 17 (18) , 6567-6582
Discovery of a series of acrylic acids and their derivatives as chemical leads for selective EP3 receptor antagonists
- 1 February 2008
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 16 (4) , 1613-1631
Design and synthesis of DPP-IV inhibitors lacking the electrophilic nitrile group
- 1 February 2008
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 16 (4) , 1613-1631
Design and synthesis of DPP-IV inhibitors lacking the electrophilic nitrile group
- 1 January 2008
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 16 (1) , 190-208
Discovery of long-acting N-(cyanomethyl)-N-alkyl-l-prolinamide inhibitors of dipeptidyl peptidase IV
- 1 January 2008
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 16 (1) , 190-208
Discovery of long-acting N-(cyanomethyl)-N-alkyl-l-prolinamide inhibitors of dipeptidyl peptidase IV
- 1 November 2007
- Published by Elsevier in Comparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology
- Vol. 148 (3) , 621-628
Cellular distribution of Mr 25,000 protein, a protein partially overlapping phosvitin and lipovitellin 2 in vitellogenin B1, and yolk proteins in Xenopus laevis oocytes and embryos
- 1 November 2007
- Published by Elsevier in Comparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology
- Vol. 148 (3) , 621-628
Cellular distribution of Mr 25,000 protein, a protein partially overlapping phosvitin and lipovitellin 2 in vitellogenin B1, and yolk proteins in Xenopus laevis oocytes and embryos
- 1 April 2007
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 15 (7) , 2631-2650
Design and synthesis of new potent dipeptidyl peptidase IV inhibitors with enhanced ex vivo duration
- 1 April 2007
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 15 (7) , 2631-2650
Design and synthesis of new potent dipeptidyl peptidase IV inhibitors with enhanced ex vivo duration